GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » EV-to-EBIT

Eledon Pharmaceuticals (FRA:2TK) EV-to-EBIT : -1.54 (As of May. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eledon Pharmaceuticals's Enterprise Value is €61.05 Mil. Eledon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-39.53 Mil. Therefore, Eledon Pharmaceuticals's EV-to-EBIT for today is -1.54.

The historical rank and industry rank for Eledon Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

FRA:2TK' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.35   Med: 0   Max: 1.52
Current: -1.54

During the past 12 years, the highest EV-to-EBIT of Eledon Pharmaceuticals was 1.52. The lowest was -2.35. And the median was 0.00.

FRA:2TK's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs FRA:2TK: -1.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Eledon Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was €7.97 Mil. Eledon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-39.53 Mil. Eledon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -495.79%.


Eledon Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Eledon Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals EV-to-EBIT Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 -7.38 0.57 0.61 0.17

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.93 0.63 0.17 -0.20

Competitive Comparison of Eledon Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Eledon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's EV-to-EBIT falls into.



Eledon Pharmaceuticals EV-to-EBIT Calculation

Eledon Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=61.051/-39.529
=-1.54

Eledon Pharmaceuticals's current Enterprise Value is €61.05 Mil.
Eledon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-39.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eledon Pharmaceuticals  (FRA:2TK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Eledon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-39.529/7.97289
=-495.79 %

Eledon Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was €7.97 Mil.
Eledon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-39.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eledon Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines